功能不良动静脉内瘘重复干预的成本效果分析
本研究基于单中心2007至2015年720例成熟动静脉内瘘的临床数据,构建Markov模型比较重复开放或经皮干预与新建AVF的成本效果。结果显示经皮干预临床效果逐次递减但成本低于新建AVF,而第二次开放再干预后新建AVF具有成本效果。
要点
- 经皮干预功能不良AVF的效果随再干预次数递减,但成本低于新建AVF。
- 开放再干预后第一次ICER为357,143美元/QALY,第二次为95,876美元/QALY。
- 第二次开放再干预后新建AVF具有成本效果。
核心结论
- 经皮干预功能不良AVF的临床效果随每次再干预而递减,但成本仍低于新建AVF。
- 数据显示第二次开放再干预后新建AVF具有成本效果。
研究设计与样本
- 单中心回顾性队列研究,纳入2007至2015年720例成熟动静脉内瘘。
- 基于临床数据参数化Markov模拟模型,比较重复干预与新建AVF的策略。
- 成本从Medicare支付方角度测量,效果指标为QALY和功能通路时间。
主要发现
- 407例(56%)AVF至少接受一次干预以维持功能通畅,首次再干预中位时间12.6个月(IQR 10-17)。
- 首次再干预后开放手术ICER为357,143美元/QALY,第二次再干预后为95,876美元/QALY。
- 经皮干预ICER从首次再干预后1,522,078美元/QALY降至第三次再干预后443,243美元/QALY。
关键数值与推荐
- 首次再干预后开放手术ICER为357,143美元/QALY,第二次再干预后为95,876美元/QALY。
- 经皮干预ICER首次再干预后1,522,078美元/QALY,第三次再干预后443,243美元/QALY。
- 支付方成本:开放手术3519至3922美元,经皮手术2134至3922美元。
临床怎么用
- 对功能不良AVF可优先考虑经皮干预以降低成本,但需注意效果随再干预次数递减。
- 第二次开放再干预后,新建AVF可能是具有成本效果的选择。
局限性
- 单中心回顾性研究,结果外推需谨慎。
- 成本基于Medicare支付方角度,其他支付体系下结论可能不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Arteriovenous fistulas (AVFs) used for hemodialysis commonly undergo multiple percutaneous and open interventions to maintain functional patency, but it is unclear whether this strategy is cost-effective. The aim of this study was to evaluate the clinical effectiveness and cost-effectiveness of performing repeated interventions vs starting a new AVF. METHODS: We reviewed all patients with mature radiocephalic, brachiocephalic, and brachiobasilic AVFs at a single academic institution between 2007 and 2015 and assessed the clinical effectiveness of each open and percutaneous intervention to maintain functional patency after the fistula was created. These data were used to parameterize a Markov simulation model to determine the cost-effectiveness for performing an open or percutaneous intervention vs creating an AVF at a new anatomic location. This model compared strategies of creating a new AVF after the first to fourth reintervention within a 1-year time window, with the reference being creation of a new AVF on the fourth reintervention. Costs were measured from Medicare's perspective, and effectiveness was measured as quality-adjusted life-years (QALYs) and time in functional access. Incremental cost-effectiveness ratios (ICERs) were calculated by taking the ratio of the difference in cost and the difference in effectiveness between two strategies. RESULTS: A total of 720 AVFs that were created during the 8-year period reached maturity, and 407 (56%) underwent at least one intervention to maintain functional patency, with the median (interquartile range) time to first reintervention of 12.6 (10-17) months. For the strategies of creating a new AVF after the first versus the fourth reintervention, payer costs ranged from $3519 to $3922 for open procedures and $2134 to $3922 for percutaneous procedures. The ICERs for open interventions on failing AVFs were $357,143/QALY after the first reintervention and $95,876/QALY after the second reintervention. The ICERs for percutaneous interventions on failing AVFs ranged from $1,522,078/QALY after the first reintervention to $443,243/QALY after the third reintervention. CONCLUSIONS: Whereas the clinical effectiveness of performing percutaneous interventions on failing AVFs diminishes after each reintervention, they are nevertheless less costly than creating a new AVF. In comparison, our data show that creating a new AVF is cost-effective after the second open reintervention procedure.
引用
- Brooke BS, Griffin CL, Kraiss LW, et al. Cost-effectiveness of repeated interventions on failing arteriovenous fistulas. J Vasc Surg. 2019. PMID: 31147114. doi:10.1016/j.jvs.2019.01.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。